Abstracts Archive - Page 894 of 2425 - ACR Meeting Abstracts

Abstract Number: 2034 • 2019 ACR/ARP Annual Meeting
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Yi Li¹, Hao Li ², Shui Lian Yu ³, Vasileios Kyttaris ⁴ and George Tsokos ⁴, ¹BIDMC, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (People's Republic), ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
Abstract Number: 2035 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
Shunichi Shiozawa¹, Ken Tsumiyama ¹, Yumi Miyazaki ², Keiichi Sakurai ³, Takahiko Horiuchi ⁴, Motohiro Oribe ⁵, Takashi Yamane ⁶, Hidetoshi Kagawa ⁷ and Kazuko Shiozawa ⁸, ¹Institute for Rheumatic Diseases, Ashiya, Japan, ²Kyushu University Beppu Hospital, Tokyo, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁵Oribe Rheumatology Clinic, Oita, Japan, ⁶Department of Rheumatology, Kakogawa Central City Hospital, Kakogawa, Japan, ⁷Rheumatology, Red Cross Society Himeji Hospital, Himeji, Japan, ⁸Rheumatic Diseases Center, Hyogo Prefectural Kakogawa Medical Center, Ashiya, Japan
Background/Purpose: We previously found in reproducible experiments in which the mice not prone to autoimmune disease were immunized repeatedly with antigen that overstimulation of CD4…
Abstract Number: 2036 • 2019 ACR/ARP Annual Meeting
Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Jie An¹, Bhargavi Duvvuri ¹, Xizhang Sun ¹, Lena Tanaka ¹, Christian Lood ¹ and Keith Elkon ¹, ¹University of Washington, Seattle
Background/Purpose: Approximately 70% of patients with Systemic Lupus Erythematosus (SLE) show a striking Type I Interferon (IFN-I) signature in peripheral blood. Although we have some…
Abstract Number: 2037 • 2019 ACR/ARP Annual Meeting
Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Theresa Lu ¹, Noa Schwartz ², Thomas Li ², William Shipman ³, Dragos Dasoveanu ³, Yong Liu ⁴, Niroshana Anandasabapathy ⁴, Henry Lee ⁴, Ali Jabbari ⁵, James Krueger ⁵, Bebak Mehrara ⁶, Keila Veiga², Kira Minkis ⁴ and David Oliver ², ¹Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery; Weill Cornell Medicine, New York, ⁴Weill Cornell Medicine (Dermatology), New York, ⁵Rockefeller University, New York, ⁶Memorial Sloan Kettering Cancer Center, New York
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on patients’ quality…
Abstract Number: 2038 • 2019 ACR/ARP Annual Meeting
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
Yangsheng Yu ¹, Michelene Hearth-Holmes ², Tammy Wang ¹, Perio D Lopez ³, Carmen Tineo ⁴, G Paulino ⁴, Michael Duryee ², Geoffrey Thiele ⁵, Ted Mikuls ⁵, Esthela Loyo ⁴ and Kaihong Su², ¹University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³Georgetown University, Washington DC, ⁴Hospital Regional Universitario José Ma Cabral Baez, San Diego, Dominican Republic, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by devastating end-organ manifestations. Cardiovascular disease (CVD) is a leading cause for premature death…
Abstract Number: 2039 • 2019 ACR/ARP Annual Meeting
High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE
Kennedy Ukadike¹, Victoria Carter ¹, John LaCava ², Martin Taylor ³, Anders Bengtsson ⁴, Christian Lood ¹ and Tomas Mustelin ¹, ¹University of Washington, Seattle, WA, ²The Rockefeller University, New York, NY, ³Massachusetts General Hospital, Boston, MA, ⁴Lund University, Lund, Sweden
Background/Purpose: The long interspersed nuclear element 1 (LINE-1) has two major open reading frames (ORFs): ORF1 encodes the RNA-binding p40 protein, and ORF2 encodes the…
Abstract Number: 2040 • 2019 ACR/ARP Annual Meeting
BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Danielle Barnes ¹, Grace Hile ¹, Tamra Reed ¹, Jianhua Liu ¹, Johann Gudjonsson ¹ and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation can drive systemic disease in SLE, thus it is essential to understand the key regulators of the aberrant inflammatory response in lupus…
Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Juliana Imgenberg-Kreuz¹, Christopher Sjöwall ², Martina Frodlund ², Iva Gunnarsson ³, Elisabet Svenungsson ⁴ and Dag Leonard ¹, ¹Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
Abstract Number: 2042 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice
Huixian Hong¹, Qi Wu ¹, PingAr Yang ¹, Bao Luo ², Alex Essman ², Oluwagbemiga Ojo ², Michael R. Crowley ³, David K. Crossman ³, Casey D. Morrow ⁴, Jeremy B. Foote ⁵, Trenton R. Schoeb ⁶, Charles O. Elson ⁷, Hui-Chen Hsu ⁸ and John D. Mountz ⁹, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ³Department of Genetics, University of Alabama at Birmingham, Birmingham, ⁴Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, ⁵Department of Microbiology, University of Alabama at Birmingham, Birmingham, ⁶Department of Genetics, Animal Resources Program, University of Alabama at Birmingham, Birmingham, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁸1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham & University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham
Background/Purpose: Intestinal microbiota dysbiosis has been implicated in the pathogenesis of autoimmune disease. How the microbiota affects the peripheral immune system leading to the development…
Abstract Number: 2043 • 2019 ACR/ARP Annual Meeting
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Natalie Sippl¹, Francesca Faustini ¹, Karine Chemin ¹, Iva Gunnarsson ² and Vivianne Malmström ³, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: Arthritis is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course.…
Abstract Number: 2044 • 2019 ACR/ARP Annual Meeting
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice
Takashi Igawa¹, Kunihiro Ichinose ¹, Ayaka Umetsu ², Kazusato Hara ³, Shin-ya Nishihata ¹, Momoko Okamoto ¹, Yushiro Endo ¹, Sosuke Tsuji ¹, Yoshika Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ⁴, George Tsokos ⁵ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki city, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki, Japan, ⁴Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Lupus nephritis　(LN) is one of the most serious complication of SLE. The alteration of the structural protein in podocytes is known as a mechanism…
Abstract Number: 2046 • 2019 ACR/ARP Annual Meeting
NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis
Sujata Ganguly¹, Umesh Kumar ², Anupam Guleria ³, Sanjukta Majumder ⁴, Sanat Phatak ¹, Smriti Chaurasia ¹, Nikhil Gupta ⁵, Sandeep Kumar ⁶, Amita Aggarwal ⁷, Dinesh Kumar ³ and Ramnath Misra ⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ²Centre of Biomedical Research SGPGIMS, Raibareli Road, Lucknow-226014, India, Lucknow, Uttar Pradesh, India, ³Centre for Biomedical Research, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Centre for Biomedical Research, Lucknow, DELHI, Delhi, India, ⁶Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Metabolomics, the study of global alterations in small metabolites is a useful tool to look for novel biomarkers. Recently, we reported a reprogramming of…
Abstract Number: 2047 • 2019 ACR/ARP Annual Meeting
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Jasvinder Singh¹ and John Cleveland ², ¹University of Alabama Medical Center, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rates of opioid abuse and associated mortality is a problem of epidemic proportion in the U.S. To our knowledge, limited data are available on…
Abstract Number: 2048 • 2019 ACR/ARP Annual Meeting
Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study
April Jorge¹, Na Lu ² and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA
Background/Purpose: Rheumatic diseases can be associated with pain and disability. An international opioid epidemic is ongoing, and prescription opioid use has been linked with increased…
Abstract Number: 2049 • 2019 ACR/ARP Annual Meeting
National Estimates of Pain Medication Use in Patients with Osteoarthritis
Mohammed Saeed¹, ¹Capital Health, Trenton, NJ
Background/Purpose: The epidemiology of pain medication use among patients with osteoarthritis is not well explored. Chronic kidney disease (CKD) modifies choice of analgesics. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].